Seavey MM - Search Results

1

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.

Stump KL, Lu LD, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Ator MA, Dorsey BD, Ruggeri BA, Seavey MM. Stump KL, et al. Among authors: seavey mm. Arthritis Res Ther. 2011 Apr 21;13(2):R68. doi: 10.1186/ar3329. Arthritis Res Ther. 2011. PMID: 21510883 Free PMC article.

2

Novel method of monitoring trace cytokines and activated STAT molecules in the paws of arthritic mice using multiplex bead technology.

Lu LD, Stump KL, Seavey MM. Lu LD, et al. Among authors: seavey mm. BMC Immunol. 2010 Nov 12;11:55. doi: 10.1186/1471-2172-11-55. BMC Immunol. 2010. PMID: 21073728 Free PMC article.

3

Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.

Lu LD, Stump KL, Wallace NH, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Mason JL, Ator MA, Dorsey BD, Ruggeri BA, Seavey MM. Lu LD, et al. Among authors: seavey mm. J Immunol. 2011 Oct 1;187(7):3840-53. doi: 10.4049/jimmunol.1101228. Epub 2011 Aug 31. J Immunol. 2011. PMID: 21880982

4

Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.

Seavey MM, Lu LD, Stump KL, Wallace NH, Ruggeri BA. Seavey MM, et al. Int Immunopharmacol. 2012 Jan;12(1):257-70. doi: 10.1016/j.intimp.2011.11.019. Epub 2011 Dec 13. Int Immunopharmacol. 2012. PMID: 22178195

5

The many faces of Janus kinase.

Seavey MM, Dobrzanski P. Seavey MM, et al. Biochem Pharmacol. 2012 May 1;83(9):1136-45. doi: 10.1016/j.bcp.2011.12.024. Epub 2011 Dec 24. Biochem Pharmacol. 2012. PMID: 22209716 Review.

6

Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer.

Seavey MM, Lu LD, Stump KL, Wallace NH, Hockeimer W, O'Kane TM, Ruggeri BA, Dobrzanski P. Seavey MM, et al. Mol Cancer Ther. 2012 Apr;11(4):984-93. doi: 10.1158/1535-7163.MCT-11-0951. Epub 2012 Feb 14. Mol Cancer Ther. 2012. PMID: 22334590

7

Animal models of systemic lupus erythematosus (SLE) and ex vivo assay design for drug discovery.

Seavey MM, Lu LD, Stump KL. Seavey MM, et al. Curr Protoc Pharmacol. 2011 Jun;Chapter 5:Unit 5.60. doi: 10.1002/0471141755.ph0560s53. Curr Protoc Pharmacol. 2011. PMID: 21935901

8

An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.

Seavey MM, Maciag PC, Al-Rawi N, Sewell D, Paterson Y. Seavey MM, et al. J Immunol. 2009 May 1;182(9):5537-46. doi: 10.4049/jimmunol.0803742. J Immunol. 2009. PMID: 19380802 Free PMC article.

9

Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105.

Wood LM, Pan ZK, Guirnalda P, Tsai P, Seavey M, Paterson Y. Wood LM, et al. Cancer Immunol Immunother. 2011 Jul;60(7):931-42. doi: 10.1007/s00262-011-1002-x. Epub 2011 Mar 23. Cancer Immunol Immunother. 2011. PMID: 21431419 Free PMC article.

10

Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.

Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y. Maciag PC, et al. Among authors: seavey mm. Cancer Res. 2008 Oct 1;68(19):8066-75. doi: 10.1158/0008-5472.CAN-08-0287. Cancer Res. 2008. PMID: 18829565 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page